Ruaro, B.; Salotti, A.; Reccardini, N.; Kette, S.; Da Re, B.; Nicolosi, S.; Zuccon, U.; Confalonieri, M.; Mondini, L.; Pozzan, R.;
et al. Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study. Pharmaceuticals 2024, 17, 119.
https://doi.org/10.3390/ph17010119
AMA Style
Ruaro B, Salotti A, Reccardini N, Kette S, Da Re B, Nicolosi S, Zuccon U, Confalonieri M, Mondini L, Pozzan R,
et al. Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study. Pharmaceuticals. 2024; 17(1):119.
https://doi.org/10.3390/ph17010119
Chicago/Turabian Style
Ruaro, Barbara, Andrea Salotti, Nicolò Reccardini, Stefano Kette, Beatrice Da Re, Salvatore Nicolosi, Umberto Zuccon, Marco Confalonieri, Lucrezia Mondini, Riccardo Pozzan,
and et al. 2024. "Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study" Pharmaceuticals 17, no. 1: 119.
https://doi.org/10.3390/ph17010119
APA Style
Ruaro, B., Salotti, A., Reccardini, N., Kette, S., Da Re, B., Nicolosi, S., Zuccon, U., Confalonieri, M., Mondini, L., Pozzan, R., Hughes, M., Confalonieri, P., & Salton, F.
(2024). Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study. Pharmaceuticals, 17(1), 119.
https://doi.org/10.3390/ph17010119
